Peter J Rossi

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi Lymphadenectomy for patients with cervical cancer: is it of value?
    Peter J Rossi
    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Surg Oncol 100:404-6. 2009
  2. ncbi A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age
    Breanne E Terakedis
    Department of Radiation Oncology, Emory University, Atlanta, GA, USA
    Am J Clin Oncol 33:619-23. 2010
  3. ncbi Prostate cancer modality time trend analyses from 1973 to 2004: a Surveillance, Epidemiology, and End Results registry analysis
    Ashesh B Jani
    Department of Radiation Oncology, Emory University, Atlanta, Georgia 30322, USA
    Am J Clin Oncol 33:168-72. 2010
  4. ncbi Stage IV prostate cancer: survival differences in clinical T4, nodal and metastatic disease
    Wayland Hsiao
    Department of Urology, Emory University School of Medicine, Atlanta, Georgia
    J Urol 184:512-8. 2010
  5. ncbi Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer
    Natalie Xu
    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Am J Clin Oncol 34:11-5. 2011
  6. ncbi Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis
    Peter J Rossi
    Department of Radiation Oncology, Emory University School of Medicine, 1365 Clifton Rd, NE, Atlanta, GA 30322, USA
    Int J Radiat Oncol Biol Phys 70:134-8. 2008
  7. ncbi Pelvic shape and prostate motion: implications for target volume design and analysis of acute toxicity
    Ashesh B Jani
    Department of Radiation Oncology, Emory University, Atlanta, GA 30322, USA
    Am J Clin Oncol 32:291-5. 2009
  8. ncbi Boost first, eliminate systematic error, and individualize CTV to PTV margin when treating lymph nodes in high-risk prostate cancer
    Peter J Rossi
    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA
    Radiother Oncol 90:353-8. 2009
  9. ncbi High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes
    Scott Edelman
    Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Int J Radiat Oncol Biol Phys 83:1473-9. 2012
  10. ncbi Applying population dynamics modeling to patients with lymph node positive prostate cancer
    Peter A S Johnstone
    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Urol 178:1952-5; discussion 1955-6. 2007

Collaborators

Detail Information

Publications16

  1. ncbi Lymphadenectomy for patients with cervical cancer: is it of value?
    Peter J Rossi
    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Surg Oncol 100:404-6. 2009
    ..The purpose of this Surveillance Epidemiology and End Results (SEER) analysis was to assess the value of lymphadenectomy (LND) in patients with cervical cancer...
  2. ncbi A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age
    Breanne E Terakedis
    Department of Radiation Oncology, Emory University, Atlanta, GA, USA
    Am J Clin Oncol 33:619-23. 2010
    ....
  3. ncbi Prostate cancer modality time trend analyses from 1973 to 2004: a Surveillance, Epidemiology, and End Results registry analysis
    Ashesh B Jani
    Department of Radiation Oncology, Emory University, Atlanta, Georgia 30322, USA
    Am J Clin Oncol 33:168-72. 2010
    ..Our objectives were to analyze time trends in the use of surgery and RT and type of RT (external beam RT [EBRT], brachytherapy [Brachy] or combination EBRT + Brachy [Combo])...
  4. ncbi Stage IV prostate cancer: survival differences in clinical T4, nodal and metastatic disease
    Wayland Hsiao
    Department of Urology, Emory University School of Medicine, Atlanta, Georgia
    J Urol 184:512-8. 2010
    ..Assignment to stage IV prostate cancer may occur by different modes, namely as T4N0M0 vs N1 vs M1 disease. We hypothesize that patients with clinical T4 disease have better outcomes than those with N1 or M1 disease...
  5. ncbi Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer
    Natalie Xu
    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Am J Clin Oncol 34:11-5. 2011
    ..Our objective was to perform a toxicity analysis of a minor dose escalation (from 75.6 to 81.0 Gy) within this "high-dose" range...
  6. ncbi Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis
    Peter J Rossi
    Department of Radiation Oncology, Emory University School of Medicine, 1365 Clifton Rd, NE, Atlanta, GA 30322, USA
    Int J Radiat Oncol Biol Phys 70:134-8. 2008
    ..To assess the role of radiotherapy (RT) in women with Stage IIIC endometrial cancer...
  7. ncbi Pelvic shape and prostate motion: implications for target volume design and analysis of acute toxicity
    Ashesh B Jani
    Department of Radiation Oncology, Emory University, Atlanta, GA 30322, USA
    Am J Clin Oncol 32:291-5. 2009
    ..To study the impact of pelvic shape on prostate motion and the implications for radiotherapy target design and treatment outcomes...
  8. ncbi Boost first, eliminate systematic error, and individualize CTV to PTV margin when treating lymph nodes in high-risk prostate cancer
    Peter J Rossi
    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA
    Radiother Oncol 90:353-8. 2009
    ..The purpose of this report is to evaluate the movement of the planning target volume (PTV) in relation to the pelvic lymph nodes (PLNs) during treatment of high-risk prostate cancer...
  9. ncbi High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes
    Scott Edelman
    Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Int J Radiat Oncol Biol Phys 83:1473-9. 2012
    ..To evaluate the impact of short-course androgen deprivation therapy (ADT) on cancer control outcomes and toxicity in intermediate-risk prostate cancer treated with dose-escalated external beam radiotherapy (high-dose radiotherapy [HDRT])...
  10. ncbi Applying population dynamics modeling to patients with lymph node positive prostate cancer
    Peter A S Johnstone
    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Urol 178:1952-5; discussion 1955-6. 2007
    ..Patients with prostate cancer and positive lymph nodes are often considered to be doomed to distant failure. We applied these models to that population to examine whether those data support this presumption...
  11. ncbi Treatment efficiency of volumetric modulated arc therapy in comparison with intensity-modulated radiotherapy in the treatment of prostate cancer
    William A Hall
    Department of Radiation Oncology and the Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    J Am Coll Radiol 10:128-34. 2013
    ..The aim of this study was to test this hypothesis by measuring the average patient in-room time with VMAT versus dynamic multileaf collimator (DMLC) IMRT...
  12. ncbi Salvage therapy for locally recurrent prostate cancer after radiation
    David M Marcus
    Department of Radiation Oncolgy, Emory University, Atlanta, Georgia, USA
    Can J Urol 19:6534-41. 2012
    ..To date, there is little data describing outcomes and toxicity associated with each of these salvage modalities...
  13. ncbi A review of low-dose-rate prostate brachytherapy--techniques and outcomes
    David M Marcus
    Department of Radiation Oncology, Emory University School of Medicine, GA 30322, USA
    J Natl Med Assoc 102:500-10. 2010
    ..As research in prostate brachytherapy continues, it is likely that this modality will play an increasingly important role in the treatment of early-stage prostate cancer patients in the future...
  14. ncbi Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT
    David M Schuster
    Department of Radiology, Emory University Hospital, 1364 Clifton Rd, Atlanta, GA 30322, USA
    Radiology 259:852-61. 2011
    ....
  15. ncbi Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone
    Peter J Rossi
    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Brachytherapy 7:286-9. 2008
    ..This report examines the relationship between pretreatment prostate-specific antigen (PSA) velocity (PSAV) and freedom from biochemical recurrence (FFBR) in men with prostate cancer treated with low-dose-rate prostate brachytherapy (LDRPB)...
  16. ncbi Performance evaluation of Calypso 4D localization and kilovoltage image guidance systems for interfraction motion management of prostate patients
    Tomi Ogunleye
    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    ScientificWorldJournal 9:449-58. 2009
    ..Implications for Calypso's role as a QA tool are discussed...